Subcutaneous · GLP-1 agonist
Loxenatide / PEG-loxenatide
14 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
14
Ongoing
2
Recruiting
2
Completed
8
Sites
10
Countries
1
Endpoints
60
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
7
Phase 2
1
Phase 2/3
1
Phase 3
3
Phase 4
1
Not applicable
1
Trials by status
Recruiting
2
Completed
8
Unknown
4
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Glycemic / diabetes
18
Safety / tolerability / PK
16
Other (unclassified)
11
Cardiometabolic biomarkers
7
Weight & body composition
5
Other clinical outcomes
3
Top 20 metrics across this asset's endpoints
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
14 of 14
Showing 1-14 of 14 trials